Streetbeat News

LIPO

Lipella Pharmaceuticals Inc.

https://www.lipella.com

Industry

Biotechnology

Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310, a formulation of tacrolimus for the treatment of oral lichen planus. The company was incorporated in 2005 and is based in Pittsburgh, Pennsylvania.

Open

2.45

Mkt cap

2.9M

Volume

16K

High

2.57

P/E Ratio

-0.49

52-wk high

12.00

Low

2.35

Div yield

N/A

52-wk low

2.21

Lipella Pharmaceuticals has completed the first cohort in its Phase 2a trial of LP-310 for treating Oral Lichen Planus and is advancing to the next dose group.

Portfolio Pulse from

November 21, 2024 | 10:45 am

Lipella Pharmaceuticals has completed the first cohort in its Phase 2a trial of LP-310 for Oral Lichen Planus, showing promising initial results. The trial will now advance to the next dose group.

Portfolio Pulse from

November 21, 2024 | 10:45 am

Lipella Pharmaceuticals Inc. has secured extended market exclusivity with the issuance of a U.S. patent for its liposomal drug delivery platform, potentially enhancing its competitive edge in the biotechnology sector.

Portfolio Pulse from

November 12, 2024 | 10:45 am

Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) has been granted a U.S. patent for its liposomal drug delivery platform, extending its market exclusivity.

Portfolio Pulse from

November 12, 2024 | 10:45 am

Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) announced a 1-for-8 reverse stock split to comply with Nasdaq's minimum bid price requirement. The split will be effective on November 7, 2024, and trading on a split-adjusted basis will begin on November 8, 2024.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2024 | 8:36 pm

In Tuesday's after-market session, several health care stocks experienced significant price movements. Biodexa Pharmaceuticals saw a remarkable 119% increase, while Petros Pharma, Helius Medical Tech, Vaccinex, Aditxt, and Gain Therapeutics also posted gains. Conversely, NewGenIvf Group, HCW Biologics, Carmell, ABVC BioPharma, Tevogen Bio Holdings, and Lipella Pharmaceuticals experienced declines.

Portfolio Pulse from Benzinga Insights

October 15, 2024 | 8:30 pm

Lipella Pharmaceuticals shares rose following the announcement of a U.S. Patent allowance for its Liposomal drug delivery platform.

Portfolio Pulse from Benzinga Newsdesk

October 15, 2024 | 1:11 pm

In Tuesday's pre-market session, several healthcare stocks experienced significant movements. Gainers included Gritstone Bio, Hoth Therapeutics, Lipella Pharmaceuticals, Enveric Biosciences, Oncternal Therapeutics, and Chemomab Therapeutics. Losers included Virpax Pharmaceuticals, Burning Rock Biotech, Mainz Biomed, CareDx, Inventiva, and Novo Integrated Sciences.

Portfolio Pulse from Benzinga Insights

October 15, 2024 | 12:08 pm

Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) has received a notice of allowance from the USPTO for its liposomal drug delivery platform, marking a significant milestone in its development of therapies for serious diseases.

Portfolio Pulse from Benzinga Newsdesk

October 15, 2024 | 9:09 am

In Thursday's after-market session, several health care stocks experienced significant price movements. Notable gainers included Cardio Diagnostics Holdings, TC BioPharm, and Seres Therapeutics, while Cue Biopharma and enVVeno Medical were among the biggest losers.

Portfolio Pulse from Benzinga Insights

September 26, 2024 | 8:31 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.